Implanet SA (IM11.BE)
| Previous close | 0.1010 |
| Open | 0.1005 |
| Bid | 0.0990 x N/A |
| Ask | 0.1490 x N/A |
| Day's range | 0.1005 - 0.1005 |
| 52-week range | 0.0201 - 0.1300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
elliquence and Implanet Form Partnership for US Distribution of Ultrasonic Bone Scalpel Olea in Endoscopic Spine Market
NEW YORK & BORDEAUX, France & CAMBRIDGE, England, September 25, 2024--Regulatory News: elliquence LLC, specializing in advanced minimally invasive surgical technologies, and Implanet (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, have jointly announced a strategic agreement for US distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine sur
- Business Wire
Implanet to Co-Exhibit Alongside 8i Robotics’ Next-Gen Robotic Solutions at NASS1 booth #2412 in Chicago
BORDEAUX, France & BOSTON, September 19, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, will share booth #2412 alongside fellow innovator 8i Robotics, pioneering the development of a multi-arm robot system for use in spine and orthopedic surgery, at the NASS meeting to be held from September 25 to 27 in Chicago. Implanet w
- Business Wire
IMPLANET Announces Its 2024 Half-year Results
BORDEAUX, France & BOSTON, September 10, 2024--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its results for the first half of the current fiscal year, ending June 30, 2024, as approved by the Board of Directors on September 9, 2024.
